8-K: NewAmsterdam Pharma Reports Q2 2025 Results, Advances Obicetrapib

NewAmsterdam Pharma announced its second quarter 2025 financial results and provided corporate updates, highlighting progress in obicetrapib's clinical development and a strong cash position.

Summary

• Revenue for the quarter ended June 30, 2025, was $19.1 million, a significant increase from $2.3 million in the same period in 2024, primarily due to a $16.1 million installment from the license agreement with Menarini.
• Net loss for the quarter ended June 30, 2025, was $17.4 million, a substantial improvement compared to a net loss of $39.0 million for the same period in 2024.
• Cash, cash equivalents, and marketable securities totaled $783.3 million as of June 30, 2025, down from $834.2 million as of December 31, 2024, primarily due to ongoing operating expenditures.
• Research and Development (R&D) expenses decreased to $27.5 million in Q2 2025 from $38.4 million in Q2 2024, mainly due to a decrease in clinical expenses, partially offset by increased personnel, pipeline expansion, and regulatory costs.
• Selling, General and Administrative (SG&A) expenses increased to $27.3 million in Q2 2025 from $16.5 million in Q2 2024, driven by higher personnel costs, investments in marketing, and intellectual property expenses.
• The European marketing authorization application (EMA) for obicetrapib, through partner Menarini, remains on track for the second half of 2025.
• The PREVAIL Phase 3 cardiovascular outcomes trial (CVOT) for obicetrapib remains on track.
• Late-breaking data from the BROADWAY and TANDEM pivotal trials were presented at EAS 2025 and simultaneously published in The New England Journal of Medicine (BROADWAY) and The Lancet (TANDEM).
• A prespecified Alzheimer's disease (AD) biomarker analysis in the BROADWAY trial showed obicetrapib significantly reduced plasma p-tau217 levels versus placebo over 12 months in both the full analysis set (p<0.002) and ApoE4 carriers (p=0.0215), with a 20.5% reduction in ApoE4/E4 carriers (p=0.010).

Sentiment

Score: 8

Explanation: The company reported significantly improved financial results with a reduced net loss and increased revenue, alongside strong positive clinical trial data for obicetrapib, including novel findings in Alzheimer's biomarkers. Key regulatory and clinical milestones are on track, and the company maintains a solid cash position, indicating strong operational progress and future potential.

Positives

• Net loss significantly reduced to $17.4 million in Q2 2025 from $39.0 million in Q2 2024.
• Revenue increased substantially to $19.1 million in Q2 2025 from $2.3 million in Q2 2024, primarily driven by a $16.1 million payment from the Menarini license agreement.
• Maintained a strong cash, cash equivalents, and marketable securities position of $783.3 million as of June 30, 2025, providing a solid financial foundation.
• Positive late-breaking data from pivotal BROADWAY and TANDEM trials were presented at EAS 2025 and published in high-impact medical journals (The New England Journal of Medicine and The Lancet).
• Obicetrapib demonstrated statistically significant reductions in p-tau217, a key Alzheimer's disease biomarker, in the BROADWAY trial, suggesting potential neurodegenerative benefits.
• The European marketing authorization application (EMA) is on track for submission in the second half of 2025.
• The PREVAIL Phase 3 cardiovascular outcomes trial remains on track, with enrollment of over 9,500 patients completed in April 2024.
• Expansion of the clinical program with the planned launch of the Phase 3 RUBENS trial later this year.

Negatives

• Cash, cash equivalents, and marketable securities decreased by $50.9 million from $834.2 million at December 31, 2024, to $783.3 million at June 30, 2025, primarily due to ongoing operating expenditures.
• Selling, General and Administrative (SG&A) expenses increased significantly to $27.3 million in Q2 2025 from $16.5 million in Q2 2024, indicating rising commercialization costs.
• While overall R&D expenses decreased, personnel expenses, non-clinical expenses related to pipeline expansion, product lifecycle management, and regulatory expenses increased within this category.

Risks

• Uncertainty regarding the outcomes of ongoing clinical trials, particularly as they relate to regulatory review and potential approval for product candidates.
• Risks associated with efforts to commercialize product candidates, including the ability to build out commercial capabilities.
• The ability to negotiate and enter into definitive agreements on favorable terms, if at all.
• The potential impact of competitive product candidates on the company's business.
• Intellectual property related claims and the ability to protect proprietary technology.
• The ability to attract and retain qualified personnel.
• The ability to continue to source raw materials for product candidates.
• Changes in domestic and foreign business, market, financial, political, and legal conditions.
• Whether topline, initial, or preliminary results from a particular clinical trial will be predictive of the final results of that trial.
• Whether results of early clinical trials will be indicative of the results of later clinical trials, or whether projections regarding clinical outcomes will reflect actual results in future clinical trials or clinical use.
• The potential for varying interpretation of the results of clinical trials and analyses.
• Global economic and political conditions.

Future Outlook

The company plans to launch the Phase 3 RUBENS trial later this year, which will evaluate obicetrapib in combination with ezetimibe in patients with type 2 diabetes and metabolic syndrome. The European marketing authorization application (EMA) through its partner Menarini is on track for the second half of 2025. Additional data from the BROADWAY, TANDEM, and BROOKLYN trials are expected to be announced over the course of 2025. The company is also focused on building out its commercial capabilities to support the potential launch of obicetrapib, if approved.

Management Comments

• "Fueled by strong momentum in the first half of 2025, obicetrapib is rapidly advancing towards patients worldwide, potentially addressing the urgent need for additional cardiovascular disease treatment options."
• "We continue to see compelling data from our Phase 3 studies, not only reinforcing obicetrapib's observed lipoprotein modifying properties including robust LDL-C reduction but also suggesting a potential role in reducing neurodegenerative risk."
• "These findings point to the possibility that obicetrapib may address the converging pathways of cardiovascular and neurovascular disease with a single, oral therapy."
• "We are also expanding our clinical program with the launch of the Phase 3 RUBENS trial planned for later this year, which will evaluate obicetrapib in combination with ezetimibe in patients with type 2 diabetes and metabolic syndrome that require additional lowering of LDL-C despite treatment with available therapy."
• "In parallel, we are focused on building out our commercial capabilities to support the potential launch of obicetrapib, if approved."
• "On the regulatory front, our EMA application through our partner Menarini remains on track."
• "With a solid foundation and strong balance sheet, we believe we are well-positioned to create long-term value for our stakeholders and deliver a novel, first-in-class LDL-C lowering therapy to millions of patients worldwide."

Industry Context

Cardiovascular disease remains the leading cause of death globally, with U.S. age-adjusted mortality rates increasing by 9% from 2019-2022, reversing a decade-long trend. Despite the availability of lipid-lowering therapies (LLTs), LDL-C target attainment remains low, with 30 million under-treated U.S. adults not at their risk-based LDL-C goal and 10 million diagnosed with elevated LDL-C not taking any LLTs. Obicetrapib aims to address this significant unmet need for a safe, well-tolerated, and convenient LDL-lowering therapy, positioning itself as a potential adjunct to statin therapy. The emerging data on Alzheimer's biomarkers also suggests a broader potential impact beyond traditional CVD, linking cardiovascular and neurovascular pathways, which could differentiate obicetrapib in the market.

Comparison to Industry Standards

• The company highlights that despite 269 million LLT prescriptions over the last 12 months, 30 million under-treated U.S. adults are not at their risk-based LDL-C goal, and 13 million have ASCVD, indicating a significant unmet need that obicetrapib aims to address.
• Less than 1 in 4 patients with ASCVD achieve an LDL-C goal of less than 70 mg/dL, and only 10% of very high-risk ASCVD patients achieve the goal below 55 mg/dL, underscoring the limitations of current therapies that obicetrapib seeks to overcome.
• Obicetrapib's observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo in multiple Phase 2 and Phase 3 trials (ROSE2, TULIP, ROSE, OCEAN, BROOKLYN, BROADWAY, TANDEM) suggests a favorable safety and efficacy profile compared to existing treatments.
• The positive data on obicetrapib's effect on plasma p-tau217 levels, an Alzheimer's disease biomarker, in the BROADWAY trial, particularly in ApoE4 carriers, presents a novel potential benefit that could differentiate it from other cardiovascular therapies and address converging pathways of cardiovascular and neurovascular disease.

Stakeholder Impact

• Shareholders: Positive clinical data, reduced net loss, and a strong cash position could increase investor confidence and potentially share price, indicating a favorable outlook.
• Patients: Potential for a novel, oral, first-in-class LDL-C lowering therapy, especially for those not adequately treated by existing therapies, and a potential new treatment pathway for neurodegenerative risk.
• Employees: Continued clinical development and commercialization efforts suggest stable to growing employment opportunities as the company advances towards potential product launch.
• Regulatory Authorities: Ongoing EMA application and future regulatory submissions will involve continued interaction and scrutiny, requiring adherence to regulatory standards.
• Partners (Menarini Group): Continued progress in clinical trials and regulatory applications strengthens the partnership, potentially leading to successful commercialization in Europe.

Next Steps

• Announce additional data from the BROADWAY, TANDEM, and BROOKLYN trials over the course of 2025.
• Launch of the Phase 3 RUBENS trial planned for later this year.
• European marketing authorization application (EMA) on track for submission in the second half of 2025.
• Continue building commercial capabilities to support the potential launch of obicetrapib, if approved.

Key Dates

Recommendation

The company has demonstrated significant progress in its clinical development programs, with positive Phase 3 data for obicetrapib, including promising new findings related to Alzheimer's disease biomarkers, which could open up a new market. Financial results show a substantial reduction in net loss and a significant increase in revenue, indicating improved operational efficiency and successful monetization of assets (Menarini agreement). With a robust cash position and key regulatory milestones on track for the near future, the company is well-positioned for potential market entry and long-term growth in a high-unmet-need therapeutic area. The combination of strong clinical efficacy, a favorable safety profile, and a clear path to commercialization makes this an attractive investment.

Keywords

NewAmsterdam Pharma, NAMS, obicetrapib, CETP inhibitor, cardiovascular disease, LDL-C, Alzheimer's disease, p-tau217, clinical trials, Phase 3, PREVAIL, BROADWAY, TANDEM, RUBENS, biopharmaceutical, financial results, Q2 2025, SEC filing, 8-K